3D Cell Culture Market by Scaffold Format (Scaffold Based and Scaffold Free System), Products (Hydrogel / Extracellular Matrix (ECM), 3D Bioreactor, 3D Petri Dish, Hanging Drop Plate, Microfluidic System, Micropatterned Surface, Microcarrier, Organ-on-Chi

3D Cell Culture Market by Scaffold Format (Scaffold Based and Scaffold Free System), Products (Hydrogel / Extracellular Matrix (ECM), 3D Bioreactor, 3D Petri Dish, Hanging Drop Plate, Microfluidic System, Micropatterned Surface, Microcarrier, Organ-on-Chip, Solid Scaffold, and Suspension System), Application Areas (Cancer Research, Drug Discovery and Toxicology, Stem Cell Research, Tissue Engineering and Regenerative Medicine), Purpose (Research Use and Therapeutic Use), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts (3rd Edition), 2020-2030

Animal cell cultures represent an integral part of the drug discovery and development process. The conventional 2 dimensional (2D) cell culturing format is still extensively used in early stage research and is instrumental in establishing initial proof-of-concept and validating mechanisms of action of pharmacological leads. However, over time, it has been demonstrated that such cultures are unable to accurately mimic the natural (in vivo) microenvironment. Moreover, cells cultured in monolayers are both morphologically and physiochemically different from their in vivo counterparts. This leads to differences in viability, growth rate, and function. Additionally, in adherent 2D culture systems, only 50% of the cell surface is exposed to the culture medium, which limits cell-to-cell and cell-to-medium interactions. In fact, a study reported that 95% of drugs that exhibited efficacy in 2D culture models failed in in vivo studies / human trials.

Advances in biotechnology and materials science have enabled the development of a variety of 3-dimensional (3D) cell culture models. These systems have been demonstrated to be capable of more accurately simulating the natural tissue microenvironment and, thereby, can help overcome most of the challenges associated with 2D systems. In addition, there are certain complex 3D cell culture models that are likely to soon replace animal models. In other words, 3D cell cultures are able to better simulate the natural tissue microenvironments, thereby, serving as better in vivo models for use in experimental research, including drug discovery / toxicity testing, development of regenerative medicine, tissue engineering, and stem cell research. This is anticipated to drive the adoption of such solutions in the foreseen future. Moreover, in a recent study, perfused 3D culture systems were used to emulate human bronchial tissue and airway cells, in order to study infectious respiratory diseases. Further, 3D cell cultures and organoid-based screening systems are being developed to facilitate the study of the pathogenesis of the novel coronavirus and support ongoing drug development efforts on this front. Based on the current trend of use, we are led to believe that the COVID-19 pandemic is likely to result in an increased demand for such solutions, presenting lucrative opportunities for companies engaged in this domain. In this context, the overall 3D cell culture market is anticipated to witness substantial growth in the coming years.

The “3D Cell Culture Market by Scaffold Format (Scaffold Based and Scaffold Free System), Products (Hydrogel / Extracellular Matrix (ECM), 3D Bioreactor, 3D Petri Dish, Hanging Drop Plate, Microfluidic System, Micropatterned Surface, Microcarrier, Organ-on-Chip, Solid Scaffold, and Suspension System), Application Areas (Cancer Research, Drug Discovery and Toxicology, Stem Cell Research, Tissue Engineering and Regenerative Medicine), Purpose (Research Use and Therapeutic Use), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts (3rd Edition), 2020-2030” report features an extensive study of the current landscape and the likely future potential of 3D culture systems, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. In addition to other elements, the study includes:
 An insightful assessment of the current market landscape of companies offering various 3D cell culture systems, along with information on a number of relevant parameters, such as year of establishment, size of employee base, geographical presence, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems). In addition, the chapter provides information related to the companies providing 3D culture related services, and associated reagents / consumables.
 A detailed assessment of the overall landscape of scaffold based products, along with information on a number of relevant parameters, such as status of development (under development, developed not commercialized, and commercialized), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, and microcarriers), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. In addition, it presents details of the companies developing scaffold based products, highlighting year of establishment, size of employee base, and geographical presence.
 A detailed assessment of the overall landscape of scaffold free products, along with information on a number of relevant parameters, such as status of development (under development, developed and not commercialized, and commercialized), type of product (attachment resistant surfaces, suspension systems and microfluidic systems), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based and polymer based), and material used for fabrication. In addition, it presents details of the companies developing scaffold free products, highlighting their year of establishment, size of employee base, and geographical presence.
 A detailed assessment of the overall landscape of 3D bioreactors, along with information on a number of relevant parameters, such as type of 3D bioreactor (single-use, perfusion, fed-batch, and fixed-bed), and typical working volume. In addition, it presents details of the companies developing 3D bioreactors, highlighting year of establishment, size of employee base, and geographical presence.
 An insightful analysis, highlighting the applications (cancer research, drug discovery and toxicology, stem cell research, tissue engineering and regenerative medicine) for which various 3D cell culture products are being developed / used.
 Elaborate profiles of prominent players (shortlisted based on number of products being offered) that are engaged in the development of 3D cell culture products. Each company profile features a brief overview of the company, along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments, and an informed future outlook.
 An analysis of the investments made in the period between 2015 and 2020, including seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, at various stages of development in small and mid-sized companies (established after 2005; with less than 200 employees) that are engaged in the development of 3D cell culture products.
 An analysis of the various partnerships related to 3D cell culture products, which have been established between 2015 and 2020 (till September), based on several parameters, such as year of agreement, type of partnership (product development / commercialization agreements, product integration / utilization agreements, product licensing agreement, research and development agreements, distribution agreements, acquisitions, joint venture and other agreements), 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactor), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems), and most active players. It also provides the regional distribution of players involved in the collaborations.
 An in-depth analysis of over 8,400 patents that have been filed / granted for 3D cell culture products, between 2015 and 2020, highlighting key trends associated with these patents, across type of patent, publication year, issuing authorities involved, CPC symbols, emerging focus areas, leading patent assignees (in terms of number of patents filed / granted), patent characteristics and geography. It also includes a detailed patent valuation analysis.
 An in-depth discussion on the classification of 3D cell culture systems, categorized as scaffold based systems (hydrogels / ECMs, solid scaffolds, micropatterned surfaces and microcarriers), scaffold free systems (attachment resistant surfaces, suspension systems and microfluidic systems) and 3D bioreactors.
 An elaborate discussion on the methods used for fabrication of 3D matrices and scaffolds, highlighting the materials used, the process of fabrication, merits and demerits, and the applications of different fabrication methods.
 Insights from an industry-wide survey, featuring inputs solicited from various experts who are directly / indirectly involved in the development of 3D cell culture products.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the 3D cell culture market. Based on multiple parameters, such as business segment, price of 3D cell culture products, and likely adoption of the 3D cell culture products, we have provided informed estimates on the likely evolution of the 3D cell culture systems market in the mid to long term, for the time period 2020-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] 3D cell culture scaffold (scaffold based systems, scaffold free systems, and 3D bioreactors), [B] type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems, and microfluidic systems), [C] area of application (cancer research, drug discovery / toxicity testing, stem cell research, and regenerative medicine / tissue engineering), [D] purpose (research use and therapeutic use), [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and RoW (Rest of the World)), and [F] leading product developers. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry and non-industry players:
 Brigitte Angres (Co-founder, Cellendes)
 Bill Anderson (President and CEO, Synthecon)
 Anonymous (President and CEO, Anonymous)
 Anonymous (Co-founder and Vice President, Anonymous)
 Scott Brush (Vice President, BRTI Life Sciences)
 Malcolm Wilkinson (Managing Director, Kirkstall)
 Ryder Clifford (Director, QGel) and Simone Carlo Rizzi (Chief Scientific Officer, QGel)
 Tanya Yankelevich (Director, Xylyx Bio)
 Jens Kelm (Chief Scientific Officer, InSphero)
 Walter Tinganelli (Group Leader, GSI)
 Darlene Thieken (Project Manager, Nanofiber Solutions)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
 Annual reports
 Investor presentations
 SEC filings
 Industry databases
 News releases from company websites
 Government policy documents
 Industry analysts’ views

While the focus has been on forecasting the market over the coming 10 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED
 Who are the leading industry players engaged in the development of 3D cell culture products?
 What are the most popular 3D cell culture products?
 What are the different applications for which 3D cell culture products are currently being developed?
 What are the key factors that are likely to influence the evolution of this market?
 What is the trend of capital investments in the 3D cell culture systems market?
 Which partnership models are commonly adopted by stakeholders in this industry?
 How is the COVID-19 pandemic likely to impact the 3D cell culture systems market?
 How is the current and future opportunity likely to be distributed across key market segments?
 What are the anticipated future trends related to 3D cell culture systems market?

CHAPTER OUTLINES
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of 3D cell culture systems market and its likely evolution in the short to mid-term and long term.
Chapter 3 provides a general introduction to 3D culture systems, covering details related to the current and future trends in the domain. The chapter highlights the different types of cell cultures, the various methods of cell culturing and their application areas. The chapter also features a comparative analysis of 2D and 3D cultures, as well as highlights the current need and advantages of 3D culture systems.

Chapter 4 provides an overview of the classification of 3D culture systems, categorized as scaffold based systems (hydrogels / ECMs, solid scaffolds, micropatterned surfaces and microcarriers), scaffold free systems (attachment resistant surfaces, suspension systems and microfluidic systems) and 3D bioreactors. It also highlights, in detail, the underlying concepts, advantages and disadvantages of the aforementioned products.

Chapter 5 presents summaries of different techniques that are commonly used for fabrication of 3D matrices and scaffolds. It further provides information on the working principle, benefits and limitations associated with each method. In addition, the chapter features key takeaways from various research studies focused on matrices fabricated using the aforementioned methods.

Chapter 6 includes information on close to 160 industry players offering various 3D cell culture products. It features detailed analyses of these companies based on year of establishment, size of employee base, geographical presence, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems). In addition, the chapter provides information the companies that offer 3D culture related services and associated reagents / consumables. It also highlights the contemporary market trends in four schematic representations, which include [A] a heat map representation illustrating the distribution of developers based on type of 3D cell culture format and company size, [B] an insightful tree map representation of the developers, distributed on the basis of type of product and company size, and [C] a world map representation highlighting the regional distribution of developer companies.

Chapter 7 includes information on close to 150 scaffold based products that are either commercialized or under development. It features detailed analyses of these products based on status of development (under development, developed and not commercialized, and commercialized, type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, and microcarriers), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. The chapter also highlights the contributions of various companies developing scaffold based products, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 8 includes information on more than 60 scaffold free products that are either commercialized or under development. It features detailed analyses of these products based on status of development (under development, developed not commercialized, and commercialized, type of product (attachment resistant surfaces, suspension systems, and microfluidic systems), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. The chapter also highlights the contributions of various companies developing scaffold free products, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 9 includes information on more than 100 3D bioreactors that are either commercialized or under development. It features detailed analyses of these products based on the type of 3D bioreactor (single-use, perfusion, fed-batch, and fixed-bed), and typical working volume. The chapter also highlights the contributions of various companies developing 3D bioreactors, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 10 presents a detailed overview and analysis on the most popular application areas, which include cancer research, drug discovery and toxicity screening, stem cell research, tissue engineering and regenerative medicine) for which various 3D cell culture products are being developed / used.

Chapter 11 features elaborate profiles of prominent players that are either engaged in the development or have developed popular scaffold based products (offering at least five hydrogel / ECM products). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 12 features elaborate profiles of prominent players that are either engaged in the development or have developed popular scaffold free products (offering at least three organ-on-chip products). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 13 features elaborate profiles of prominent players that are either engaged in the development or have developed 3D bioreactors (offering at least two bioreactors). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 14 features an analysis of the investments made in the period between 2015 and 2020, including seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, at various stages of development in small and mid-sized companies (established after 2005; with less than 200 employees) that are engaged in the development of 3D cell culture products, highlighting the growing interest of the venture capital community and other strategic investors, in this domain.

Chapter 15 features in-depth analysis and discussion of the various partnerships inked between the players in this market, during the period, 2015 and 2020 (till September), based on several parameters, such as year of agreement, type of partnership (product development / commercialization agreements, product integration / utilization agreements, product licensing agreement, research and development agreements, distribution agreements, acquisitions, joint venture and other agreements), 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactor), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems), and most active players. It also provides the regional distribution of players involved in the collaborations.

Chapter 16 provides an in-depth patent analysis presenting an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered over 8,400 patents that have been filed / granted for 3D cell culture products, since 2015, highlighting key trends associated with these patents, across type of patents, publication year, geographical location, type of applicants, issuing authorities involved, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted / filed in the given time period), patent characteristics and geography. It also includes a detailed patent valuation analysis.

Chapter 17 presents an insightful market forecast analysis, highlighting the likely growth of 3D cell culture systems market, for the time period 2020-2030. In order to provide an informed future outlook, our projections have been segmented on the basis of [A] 3D cell culture scaffold (scaffold based systems, scaffold free systems, and 3D bioreactors), [B] type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems, and microfluidic systems), [C] area of application (cancer research, drug discovery / toxicity testing, stem cell research, and regenerative medicine / tissue engineering), [D] purpose (research use and therapeutic use), [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and RoW (Rest of the World)), and [F] leading product developers.

Chapter 18 presents insights from the survey conducted for this study. We invited over 150 stakeholders involved in the development of 3D cell culture systems. The participants, who were primarily Founder / CXO / Senior Management level representatives of their respective companies, helped us develop a deeper understanding on the nature of their products / services and the associated commercial potential.

Chapter 19 summarizes the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the 3D cell culture systems market.

Chapter 20 is a collection of transcripts of interviews conducted with various stakeholders in the industry. The chapter provides a brief overview of the companies and details of interviews held with Brigitte Angres (Co-founder, Cellendes), Bill Anderson (President and CEO, Synthecon), anonymous (President and CEO, Anonymous), anonymous (Co-founder and Vice President, Anonymous), Scott Brush (Vice President, BRTI Life Sciences), Malcolm Wilkinson (Managing Director, Kirkstall), Ryder Clifford (Director, QGel) and Simone Carlo Rizzi (Chief Scientific Officer, QGel), Tanya Yankelevich (Director, Xylyx Bio), Jens Kelm (Chief Scientific Officer, InSphero), Walter Tinganelli (Group Leader, GSI), and Darlene Thieken (Project Manager, Nanofiber Solutions)
Chapter 21 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 22 is an appendix, which contains the list of companies and organizations mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS

The following companies / organizations have been mentioned in this report.

1. 101Bio
2. 3D Biomatrix
3. 3D Biotek
4. 3D Biotechnology Solutions
5. 3Dnamics
6. 4Dcell
7. 4titude
8. AbbVie Ventures
9. abc biopply
10. ABL Europe
11. Åbo Akademi University
12. Abstraction Ventures
13. Abzena
14. Accellta
15. Advanced BioMatrix
16. Advanced Regenerative Manufacturing Institute (ARMI)
17. Advanced Scientifics
18. Aetos Biologics
19. Afirmus Biosource
20. AGC
21. Agency for Science, Technology and Research (A*STAR)
22. AIM Biotech
23. Akero Therapeutics
24. Akron Biotech
25. Alector
26. Allevi
27. Alnylam Pharmaceuticals
28. American Laboratory Products
29. Alphabioregen
30. ALS Investment Fund
31. AlveoliX
32. AMS Biotechnology
33. AnaPath Services
34. Angel Investors
35. AngelMD
36. Angels 5K
37. Angels in MedCity
38. Angels Santé
39. Anthrogenesis
40. Aquitaine Science Transfert
41. Aquiti Gestion
42. AR Brown
43. ARL Design
44. ARTeSYN Biosolutions
45. AstraZeneca
46. Arizona State University
47. ATEL Ventures
48. Atera
49. Avantor
50. AxoSim
51. AXT
52. Axxicon
53. BASF
54. Bayer
55. B-CULTURE
56. BEOnChip
57. Bio-Byblos Biomedical
58. BioCat
59. BioConcept
60. BIOFABICS
61. Biogelx
62. Bioinspired Solutions
63. BioInvent International
64. BIOKÉ
65. BioLamina
66. Biomaterials USA
67. Biomerix
68. BiomimX
69. Biopredic International
70. BioTek Instruments
71. BiSS TGT
72. Bonus BioGroup
73. Bpifrance
74. BRAIN
75. BrainXell
76. Brammer Bio
77. Braveheart Investment Group
78. Bristol-Myers Squibb
79. Broad Institute
80. BRTI Life Sciences
81. Cambridge Bioscience
82. University of Cambridge
83. CarThera
84. Cedars-Sinai Medical Center
85. Celartia
86. Cell Applications
87. Cell Culture
88. CELLEC BIOTEK
89. Cellendes
90. Cellevate
91. CELLnTEC
92. CellSpring
93. CellSystems
94. CelVivo
95. Center for the Advancement of Science in Space
96. CESCO Bioengineering
97. Charles River Laboratories
98. Cherry Biotech
99. China Regenerative Medicine International
100. CITIC Securities
101. CN Bio Innovations
102. CN Innovations
103. Collagen Solutions
104. Comune di Milano
105. Corning Life Sciences
106. Cosmo Bio
107. CELLphenomics
108. Commonwealth Serum Laboratories
109. Curi Bio
110. Cyprio
111. Cyprotex
112. Cytiva
113. Danaher
114. Deepbridge Capital
115. Demcon
116. United States Department of Defense
117. Development Bank of Wales
118. DiPole Materials
119. Downing Ventures
120. Government of the Netherlands
121. Executive Agency for Small and Medium-sized Enterprises (EASME)
122. EBERS
123. Ectica Technologies
124. EDITHGEN
125. Electrospinning
126. Emulate
127. Enso Discoveries
128. Eppendorf
129. Esco Aster
130. Esperante
131. Ethicon
132. European Life Sciences Growth Fund (ELSGF)
133. European Commission
134. European Union
135. Eurostars
136. EU-ToxRisk
137. Eva Scientific
138. Evotec
139. faCellitate
140. Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
141. Fennik Life Sciences
142. Ferentis
143. FHNW University
144. FiberCell Systems
145. Fibralign
146. Finep
147. Finesse Solutions
148. Finovam Gestion
149. Flexcell International
150. Foundation for Technological Innovation
151. Founder
152. Founders Fund
153. Freeline
154. French Government
155. Frequency Therapeutics
156. FroggaBio
157. Fujifilm
158. FUJIFILM Wako Pure Chemical
159. Funakoshi
160. Gabriel Investments
161. Galapagos
162. GALIA Gestion
163. Gamma 3
164. Gelmetix
165. Gelomics
166. Gemini Bio
167. Gemstone Biotherapeutics
168. Genome Institute of Singapore
169. Georgia Research Alliance
170. Global Cell Solutions
171. Government of China
172. Great Stuff Ventures
173. GSI
174. GlaxoSmithKline
175. HµREL
176. Hamilton
177. Harvard Apparatus
178. Harvard College
179. HCS Pharma
180. Helvoet
181. Heraeus Medical
182. Hesperos
183. Histogenics
184. Human Models for Analysis of Pathways (HMAPs) Center
185. Hokkaido Soda
186. HP Wild Holding
187. Hubrecht Organoid Technology
188. Humanetics
189. Hyamedix
190. ibidi
191. IMSS-Gulf Bio Analytical
192. INITIO CELL
193. Innovate UK
194. Innovation Fund Denmark
195. Inova Health System
196. inRegen
197. InSphero
198. Invitrocue
199. InvivoSciences
200. Ionis Pharmaceuticals
201. Irdi Soridec Gestion
202. Janssen Biotech
203. Japan Vilene Company
204. Jellagen Marine Biotechnologies
205. Johns Hopkins University
206. JRI Orthopaedics
207. Kero
208. Kim & Friends
209. Kirkstall
210. KIYATEC
211. KOKEN
212. Koninklijke Nederlandse Akademie Van Wetenschappen
213. Kuraray
214. LabCorp
215. Laconia
216. LAMBDA Laboratory Instruments
217. Lantern Pharma
218. Lawrence J. Ellison Institute for Transformative Medicine
219. LBA Healthcare Management
220. Lena Biosciences
221. LFB Biomanufacturing
222. Life Technologies
223. Lifecore Biomedical
224. LifeNet Health
225. Laboratory for Integrated Micro Mechatronic Systems
226. Lineage Cell Therapeutics
227. Locate Bio
228. London School of Hygiene & Tropical Medicine
229. Lonza
230. Lund University
231. LuoLabs
232. Manchester BIOGEL
233. University of Mannheim
234. Maryland Momentum Fund
235. Massachusetts Institute of Technology
236. MassChallenge
237. MatTek Life Sciences
238. MBL International
239. GlassWall Syndicate
240. Menicon Life Science
241. Merck Accelerator
242. Merck Millipore
243. Michael J. Fox Foundation
244. Michigan Technological University
245. Micronit
246. MicroTissues
247. Midven
248. MIMETAS
249. Minerva Business Angel Network
250. Molecular Devices
251. Maryland Stem Cell Research Fund (MSCRF)
252. MTTlab
253. Nanobiose
254. Nano Dimension
255. Nanofiber Solutions
256. Nanogaia
257. National Aeronautics and Space Administration
258. National Center for Advancing Translational Sciences
259. National Institute of Health
260. National Institute on Aging
261. National Institutes for Food and Drug Control
262. National Science Foundation
263. National University Hospital
264. National University of Singapore
265. National Centre for the Replacement, Refinement and Reduction of Animals in Research
266. Neuromics
267. New Orleans BioFund
268. Newable Private Investing
269. Nexcelom Bioscience
270. Nord France Amorquage
271. Invest Northern Ireland
272. Northwick Park Institute for Medical Research
273. Nortis
274. Nova Biomedical
275. Novartis Venture Fund
276. Noviocell
277. Nucleus Biologics
278. NYU Winthrop Hospital
279. Olaregen Therapeutix
280. OMNI Life Science
281. Oregon Health & Science University
282. Organovo
283. Orthomimetics
284. OS Fund
285. Oxford MEStar
286. Pairnomix
287. Pall Corporation
288. Path BioAnalytics
289. PBS Biotech
290. Peak Capital Advisors
291. Pelo Biotech
292. Pensees
293. PepGel
294. Percell Biolytica
295. PerkinElmer
296. Pfizer
297. PHI
298. Pitch@Palace
299. PL BioScience
300. Plasticell
301. Pluristem Therapeutics
302. Portugal Ventures
303. Precision Biologics
304. Premedical Laboratories
305. Primorigen Biosciences
306. Principia SGR
307. ProBio
308. ProBioGen
309. Prodizen
310. PromoCell
311. Protista International
312. QGel Bio
313. QIAGEN (Suzhou)
314. Quintech Life Sciences
315. PT Rajawali Medika Mandiri
316. RASA
317. React4life
318. Real Research
319. RealBio Technology
320. Regemat3D
321. Repligen
322. REPROCELL
323. Research Without Animal Experiment
324. Revivocell
325. Rigenerand
326. Roche
327. RoosterBio
328. Roswell Park Comprehensive Cancer Center
329. Sanofi Ventures
330. SARSTEDT
331. Sartorius
332. S-BIO
333. ScienCell
334. SciFi VC
335. SciKon Innovation
336. Scinus Cell Expansion
337. Scottish Investment Bank
338. Seres Therapeutics
339. Shanghai Cienle Medical Technology
340. Shanghai Institute of Materia Medica
341. Shanghai Institute of Biochemistry and Cell Biology
342. Siemens Technology
343. Sigma-Aldrich
344. SKE Research Equipment
345. SmiLe Incubator
346. SoloHill Engineering
347. Spheritech
348. Spiber Technologies
349. Start-Up Chile
350. State Key Laboratory of Experimental Hematology
351. StemCell Systems
352. STEMCELL Technologies
353. Stemmatters
354. StemoniX
355. StemTek Therapeutics
356. SUN bioscience
357. Commission for Technology and Innovation
358. Swiss Federal Laboratories for Materials Science and Technology
359. SyndicateRoom
360. Synthecon
361. SynVivo
362. TA Instruments
363. Takeda
364. Tantti Laboratory
365. tebu-bio
366. TEDCO
367. Terumo
368. Texas Tech University Health Sciences Center
369. Development Bank of Wales
370. Ministry of Higher Education, Research and Innovation (France)
371. The Idea Village
372. Institute for Molecular Medicine Finland
373. Mario Negri Institute for Pharmacological Research
374. University of Alberta
375. University of Bath
376. University of Brescia
377. University of Bristol
378. University of Manchester
379. University of Milan
380. University of Strathclyde
381. University of Zurich
382. TheWell Bioscience
383. Thermo Fisher Scientific
384. Tianjin Weikai Biological Engineering
385. Tissue Click
386. TissueLabs
387. TissUse
388. Tokyo Future Style
389. TPG
390. TreeFrog Therapeutics
391. Trevigen
392. Triumvirate Environmental
393. Technical University of Berlin
394. Twinhelix
395. UK Innovation & Science Seed Fund
396. Science and Technology Facilities Council (STFC)
397. UK Science and Technology Facilities Council
398. University of Genoa
399. University College London
400. University Hospital Zurich
401. Stanford University
402. University of Arkansas for Medical Sciences
403. University of California
404. University of Central Florida
405. University of Nottingham
406. The University of Sheffield
407. University of Washington School of Pharmacy
408. University of Zurich
409. UPM Biomedicals
410. U.S. Small Business Administration
411. UW Medicine
412. VA Portland Health Care System
413. Vanderbilt University
414. Venture Kick
415. VentureSouth
416. Venturecraft
417. Viscofan BioEngineering
418. Visikol
419. Vivo Biosciences
420. VWR
421. Wake Forest Institute for Regenerative Medicine
422. Women Who Tech
423. XAnge
424. Xenos
425. XP Biomed
426. Xylyx Bio
427. Zhejiang University
428. zPREDICTA


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Cell Cultures
3.2.1. Primary Cell Cultures
3.2.2. Cell Lines
3.3. Morphology of Cells in Culture
3.4. Transition from 2D to 3D Cell Cultures
3.5. Overview of 3D Cell Culturing
3.5.1. Components of the Extracellular Matrix (ECM)
3.5.2. In Vitro Cell Culturing
3.5.3. Selection of Culture Format
3.6. Establishment and Maintenance of Cell Cultures
3.6.1. Isolating Cells from Tissues
3.6.2. Maintaining Cells in Culture
3.6.3. Sub-Culturing / Passaging
3.6.4. Cryogenic Storage
3.7. Requirements for Maintaining the Health of Cell Cultures
3.7.1. Safety Guidelines in a Cell Culture Facility
3.7.2. Cell Culture Health and Optimal Conditions for Growth
3.7.3. Concerns Related to Cross Contamination
3.7.4. Methods to Prevent Contamination
3.8. Need for 3D Cell Culture Systems
3.8.1. Model Systems
3.8.2. Drug Discovery and Preclinical Research
3.8.3. Cancer Research
3.8.4. Virology Research
3.8.5. Genetic Engineering and Gene Therapy Research
3.9. Advantages and Limitations of 3D Cell Culture Systems
3.10. Future Perspectives
4. CLASSIFICATION OF 3D CELL CULTURE SYSTEMS
4.1. 3D Cell Culture Classification
4.2. Scaffold based 3D Cell Cultures
4.2.1. Hydrogels / ECM Analogs
4.2.2. Solid Scaffolds
4.2.3. Micropatterned Surfaces
4.2.4. Microcarriers
4.3. Scaffold Free 3D Cell Cultures
4.3.1. Attachment Resistant Surfaces
4.3.2. Suspension Culture Systems
4.3.2.1. Hanging Drop Plates
4.3.2.2. Magnetic Levitation and 3D Bioprinting
4.3.3. Microfluidic Surfaces and Organs-on-Chips
4.3.4. 3D Bioreactors
4.4. Organoids
5. FABRICATION OF 3D MATRICES AND SCAFFOLDS
5.1. Chapter Overview
5.2. Methods for Fabricating Porous Scaffolds
5.2.1. Particulate Leaching
5.2.2. Solvent Casting
5.2.3. Emulsion Templating
5.2.4. Gas Foaming
5.2.5. Melt Molding
5.2.6. Microsphere Sintering
5.3. Methods for Fabricating Fibrous Scaffolds
5.3.1. Electrospinning
5.3.2. Phase Separation
5.3.3. Self-Assembly
5.3.4. Fiber Mesh and Fiber Bonding
5.4. Methods for Fabricating Hydrogels
5.4.1. Gelation
5.4.2. Solvent Casting and Particulate Leaching
5.4.3. Gas Foaming
5.4.4. Freeze Drying
5.4.5. Co-polymerization / Crosslinking Methods
5.4.6. Microfluidics
5.5. Methods for Fabricating Custom Scaffolds
5.5.1. Stereo-Lithography
5.5.2. 3D Bioprinting and Selective Laser Sintering (SLS)
5.5.3. Fused Deposition Modeling
5.5.4. Membrane Lamination
5.5.5. Rapid Prototyping / Solid Free-Form Technique
5.6. Methods for Fabricating Microspheres
5.6.1. Solvent Evaporation
5.6.2. Single and Double Emulsification
5.6.3. Particle Aggregation
5.7. Methods for Fabricating Native Scaffolds
5.7.1. Decellularization
6. 3D CELL CULTURE SYSTEMS: DEVELOPER LANDSCAPE
6.1. Chapter Overview
6.2. 3D Cell Culture System Developers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by 3D Cell Culture Format
6.2.5. Analysis by Type of Product
6.3. Heat Map Representation: Analysis by 3D Cell Culture Format and Location of Headquarters
6.4. Tree Map Representation: Analysis by Company Size and Type of Product
6.5. World Map Representation: Analysis by Location of Regional Headquarters
6.6. 3D Cell Cultures: List of Service Providers
6.7. 3D Cell Cultures: List of Assays, Kits and Reagents
7. MARKET LANDSCAPE: SCAFFOLD BASED PRODUCTS
7.1. Chapter Overview
7.2. Scaffold based Products: Overall Market Landscape
7.2.1. Analysis by Status of Development
7.2.2. Analysis by Type of Product
7.2.3. Analysis by Source of 3D Cultured Cells
7.2.4. Analysis by Method Used for Fabrication
7.2.5. Analysis by Material Used for Fabrication
7.2.6. Analysis by Type of Product and Source of 3D Cultured Cells
7.2.7. Analysis by Type of Product and Method Used for Fabrication
7.3. Scaffold Based Products: Developer Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.4. Leading Developers: Analysis by Number of Scaffold based Products
7.5. Tree Map Representation: Analysis by Type of Product and Company Size
8. MARKET LANDSCAPE: SCAFFOLD FREE PRODUCTS
8.1. Chapter Overview
8.2. Scaffold Free Products: Overall Market Landscape
8.2.1. Analysis by Status of Development
8.2.2. Analysis by Type of Product
8.2.3. Analysis by Source of 3D Cultured Cells
8.2.4. Analysis by Method Used for Fabrication
8.2.5. Analysis by Material Used for Fabrication
8.2.6. Analysis by Type of Product and Source of 3D Cultured Cells
8.2.7. Analysis by Type of Product and Method Used for Fabrication
8.3. Scaffold Free Products: Developer Landscape
8.3.1. Analysis by Year of Establishment
8.3.2. Analysis by Company Size
8.3.3. Analysis by Location of Headquarters
8.4. Leading Developers: Analysis by Number of Scaffold Free Products
8.5. Tree Map Representation: Analysis by Type of Product and Company Size
9. MARKET LANDSCAPE: 3D BIOREACTORS
9.1. Chapter Overview
9.2. 3D Bioreactors: Overall Market Landscape
9.2.1. Analysis by Type of 3D Bioreactor
9.2.2. Analysis by Working Volume
9.3. 3D Bioreactors: Developer Landscape
9.3.1. Analysis by Year of Establishment
9.3.2. Analysis by Company Size
9.3.3. Analysis by Location of Headquarters
9.4. Leading Developers: Analysis by Number of 3D Bioreactors
10. KEY APPLICATION AREAS
10.1. Chapter Overview
10.2. 3D Cell Culture Systems in Cancer Research
10.2.1. Need for 3D Culture Systems in Cancer Research
10.2.1.1. Improving Cancer Drug Screening with 3D Culture Systems
10.3. 3D Cell Culture Systems in Drug Discovery and Toxicity Screening
10.3.1. Drug Development Studies
10.3.2. Toxicity Screening
10.3.2.1. 3D Liver Models
10.3.2.2. Other 3D Models
10.4. 3D Cell Culture Systems in Stem Cell Research
10.4.1. Potential of 3D Culture Systems in Stem Cell Differentiation
10.4.2. In Vitro 3D Microenvironment to Induce Embryoid Body Formation
10.5. 3D Cell Cultures in Regenerative Medicine and Tissue Engineering
10.6. 3D Cell Culture Systems: Analysis by Key Application Areas
10.6.1. 3D Cell Culture Systems: Analysis by Key Application Areas and 3D Cell Culture Format
10.6.1.1. Scaffold based 3D Products: Analysis by Key Application Areas
10.6.1.2. Scaffold Free 3D Products: Analysis by Key Application Areas
10.6.1.3. 3D Bioreactors: Analysis by Key Application Areas
11. COMPANY PROFILES: SCAFFOLD BASED PRODUCTS (HYDROGEL / ECM DEVELOPERS)
11.1. Chapter Overview
11.1.1. 3D Biotek
11.1.1.1. Company Overview
11.1.1.2. Product Portfolio
11.1.1.3. Recent Developments and Future Outlook
11.1.2. Advanced BioMatrix
11.1.2.1. Company Overview
11.1.2.2. Product Portfolio
11.1.2.3. Recent Development and Future Outlook
11.1.3. Alphabioregen
11.1.3.1. Company Overview
11.1.3.2. Product Portfolio
11.1.3.3. Recent Developments and Future Outlook
11.1.4. Corning Life Sciences
11.1.4.1. Company Overview
11.1.4.2. Product Portfolio
11.1.4.3. Recent Developments and Future Outlook
11.1.5. REPROCELL
11.1.5.1. Company Overview
11.1.5.2. Product Portfolio
11.1.5.3. Recent Developments and Future Outlook
12. COMPANY PROFILES: SCAFFOLD FREE PRODUCTS (ORGAN-ON-CHIP DEVELOPERS)
12.1. Chapter Overview
12.1.1. CN Bio Innovations
12.1.1.1. Company Overview
12.1.1.2. Financial Information
12.1.1.3. Product Portfolio
12.1.1.4. Recent Developments and Future Outlook
12.1.2. Emulate
12.1.2.1. Company Overview
12.1.2.2. Financial Information
12.1.2.3. Product Portfolio
12.1.2.4. Recent Developments and Future Outlook
12.1.3. InSphero
12.1.3.1. Company Overview
12.1.3.2. Financial Information
12.1.3.3. Product Portfolio
12.1.3.4. Recent Developments and Future Outlook
12.1.4. Mimetas
12.1.4.1. Company Overview
12.1.4.2. Financial Information
12.1.4.3. Product Portfolio
12.1.4.4. Recent Developments and Future Outlook
12.1.5. TissUse
12.1.5.1. Company Overview
12.1.5.2. Product Portfolio
12.1.5.3. Recent Developments and Future Outlook
13. COMPANY PROFILES: 3D BIOREACTORS
13.1. Chapter Overview
13.2. BISS TGT
13.2.1. Company Overview
13.2.2. Product Portfolio
13.2.3. Recent Developments and Future Outlook
13.3. Celartia
13.3.1. Company Overview
13.3.2. Product Portfolio
13.3.3. Recent Developments and Future Outlook
13.4. Cell Culture
13.4.1. Company Overview
13.4.2. Product Portfolio
13.4.3. Recent Developments and Future Outlook
13.5. Cesco Bioengineering
13.5.1. Company Overview
13.5.2. Product Portfolio
13.5.3. Recent Developments and Future Outlook
13.6. Flexcell International
13.6.1. Company Overview
13.6.2. Product Portfolio
13.6.3. Recent Developments and Future Outlook
13.7. PBS Biotech
13.7.1. Company Overview
13.7.2. Product Portfolio
13.7.3. Recent Developments and Future Outlook
13.8. Synthecon
13.8.1. Company Overview
13.8.2. Product Portfolio
13.8.3. Recent Developments and Future Outlook
14. FUNDING AND INVESTMENT ANALYSIS
14.1. Chapter Overview
14.2. Types of Funding
14.3. 3D Cell Culture Systems: Funding and Investment Analysis
14.3.1. Analysis by Number of Funding Instances
14.3.2. Analysis by Amount Invested
14.3.3. Analysis by Type of Funding
14.3.4. Analysis by 3D Cell Culture Format
14.3.5. Analysis by Type of Product
14.3.6. Analysis by Geography
14.3.7. Most Active Players: Analysis by Number of Funding Instances
14.3.8. Most Active Players: Analysis by Amount of Funding
14.3.9. Most Active Investors: Analysis by Number of Instances
14.4 Concluding Remarks
15. PARTNERSHIPS AND COLLABORATIONS
15.1. Chapter Overview
15.2. Partnership Models
15.3. 3D Cell Culture Systems: Recent Partnerships and Collaborations
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.2.1. Analysis by Year of Partnership and Type of Partnership
15.3.2.2. Analysis by Company Size and Type of Partnership
15.3.3. Analysis by Type of Partner
15.3.3.1. Analysis by Year of Partnership and Type of Partner
15.3.3.2. Analysis by Type of Partnership and Type of Partner
15.3.4. Analysis by 3D Cell Culture Format
15.3.4.1. Analysis by Year of Partnership and 3D Cell Culture Format
15.3.4.2. Analysis by Type of Partnership and 3D Cell Culture Format
15.3.5. Analysis by Type of Product
15.3.5.1. Analysis by Year of Partnership and Type of Product
15.3.5.2. Analysis by Type of Partnership and Type of Product
15.3.6. Most Active Players: Analysis by Number of Partnerships
15.3.7. Regional Analysis
15.3.8. Intercontinental and Intracontinental Agreements
16. PATENT ANALYSIS
16.1. Chapter Overview
16.2. Scope and Methodology
16.3. 3D Cell Culture Systems: Patent Analysis
16.3.1. Analysis by Type of Patent
16.3.2. Analysis by Publication Year
16.3.3. Analysis by Issuing Authority
16.3.4. Analysis by CPC Symbols
16.3.5. Emerging Focus Area
16.3.6. Leading Players: Analysis by Number of Patents
16.4. 3D Cell Culture Systems: Patent Valuation Analysis
16.5. Leading Patents: Analysis by Number of Citations
17. MARKET FORECAST
17.1. Chapter Overview
17.2. Forecast Methodology and Key Assumptions
17.3. Impact of COVID-19 Pandemic on Global 3D Cell Culture Market
17.4. Global 3D Cell Culture Market, 2020-2030
17.5. Global 3D Cell Culture Market: Distribution by Business Segment
17.5.1. 3D Cell Culture Systems Market, 2020-2030
17.5.2. 3D Cell Culture Consumables Market, 2020-2030
17.5.3. 3D Cell Culture Services Market, 2020-2030
17.6. Global 3D Cell Culture Systems Market: Distribution by 3D Cell Culture Format
17.6.1. 3D Cell Culture Systems Market for Scaffold based Products, 2020-2030
17.6.2. 3D Cell Culture Systems Market for Scaffold Free Products, 2020-2030
17.6.3. 3D Cell Culture Systems Market for 3D Bioreactors, 2020-2030
17.7. Global 3D Cell Culture Systems Market: Distribution by Type of Product
17.7.1. 3D Cell Culture Systems Market for Attachment Resistant Surfaces, 2020-2030
17.7.2. 3D Cell Culture Systems Market for Hydrogels / ECMs, 2020-2030
17.7.3 3D Cell Culture Systems Market for Micropatterned Surface, 2020-2030
17.7.4. 3D Cell Culture Systems Market for Microcarriers, 2020-2030
17.7.5. 3D Cell Culture Systems Market for Microfluidic Systems, 2020-2030
17.7.6. 3D Cell Culture Systems Market for Solid Scaffolds, 2020-2030
17.7.7. 3D Cell Culture Systems Market for Suspension Culture Systems, 2020-2030
17.8. Global 3D Cell Culture Systems Market: Distribution by Area of Application
17.8.1. 3D Cell Culture Systems Market for Cancer Research, 2020-2030
17.8.2 3D Cell Culture Systems Market for Drug Discovery and Toxicity Testing, 2020-2030
17.8.3. 3D Cell Culture Systems Market for Stem Cell Research, 2020-2030
17.8.4. 3D Cell Culture Systems Market for Regenerative Medicine and Tissue Engineering, 2020-2030
17.9. Global 3D Cell Culture Systems Market: Distribution by Purpose
17.9.1. 3D Cell Culture Systems Market for Research Use, 2020-2030
17.9.2 3D Cell Culture Systems Market for Therapeutic Use, 2020-2030
17.10. Global 3D Cell Culture Systems Market: Distribution by Geography
17.10.1. 3D Cell Culture Systems Market in North America, 2020-2030
17.10.2 3D Cell Culture Systems Market in Europe, 2020-2030
17.10.3. 3D Cell Culture Systems Market in Asia-Pacific, 2020-2030
17.10.4. 3D Cell Culture Systems Market in Latin America, 2020-2030
17.10.4. 3D Cell Culture Systems Market in Middle East and North Africa (MENA), 2020-2030
17.10.5. 3D Cell Culture Systems Market in Rest of the World, 2020-2030
17.11. Global 3D Cell Culture Systems Market: Distribution by Leading Players, 2020
17.12. Concluding Remarks
18. SURVEY ANALYSIS
18.1. Chapter Overview
18.2. Overview of Respondents
18.2.1. Designation of Respondents
18.3. Survey Insights
18.3.1. 3D Cell Culture Format
18.3.2. Type of Product(s) Offered
18.3.3. Status of Development of Product(s)
18.3.4. Source of 3D Cultured Cells
18.3.5. Method Used for Fabrication
18.3.6. Area(s) of Application
18.3.7. Services Offered for 3D Cell Cultures
18.3.8. Current and Future Market Opportunity
19. CONCLUSION
20. EXECUTIVE INSIGHTS
20.1. Chapter Overview
20.2. Cellendes
20.2.1. Company Snapshot
20.2.2. Interview Transcript: Brigitte Angres, Co-founder
20.3. Synthecon
20.3.1. Company Snapshot
20.3.2. Interview Transcript: Bill Anderson, President and CEO
20.4. Anonymous
20.4.1. Interview Transcript: Anonymous, President and CEO
20.5. Anonymous
20.5.1. Interview Transcript: Anonymous, Co-founder and Vice President
20.6. BRTI Life Sciences
20.6.1. Company Snapshot
20.6.2. Interview Transcript: Scott Brush, Vice President
20.7. Kirkstall
20.7.1. Company Snapshot
20.7.2. Interview Transcript: Malcolm Wilkinson, Managing Director
20.8. QGel
20.8.1. Company Snapshot
20.8.2. Interview Transcript: Ryder Clifford, Director and Simone Carlo Rizzi, Chief Scientific Officer
20.9. Xylyx Bio
20.9.1. Company Snapshot
20.9.2. Interview Transcript: Tanya Yankelevich, Director
20.10. InSphero
20.10.1. Company Snapshot
20.10.2. Interview Transcript: Jens Kelm, Chief Scientific Officer
20.11. GSI
20.11.1. Company Snapshot
20.11.2. Interview Transcript: Walter Tinganelli, Group Leader
20.12. Nanofiber Solutions
20.12.1. Company Snapshot
20.12.2. Interview Transcript: Darlene Thieken, Project Manager
21. APPENDIX I: TABULATED DATA
22. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 3.1 Classification of Cell Cultures
Figure 3.2 Types of 2D and 3D Cell Culture Systems
Figure 3.3 Key Components of ECM
Figure 3.4 Factors Influencing the Selection of 3D Cell Culture Systems
Figure 3.5 Methods Used for Isolation of Cells from Tissues
Figure 3.6 Methods Used for Cryogenic Storage
Figure 3.7 Required Biosafety Levels for Cell Cultures
Figure 3.8 Key Applications of Cell Cultures
Figure 3.9 Shapes of 3D Spheroids Generated via 3D Cell Culture Systems
Figure 3.10 Advantages and Limitations of 3D Cell Culture Systems
Figure 4.1 Classification of 3D Cell Culture Systems
Figure 4.2 Natural Components of ECM Used for Fabrication of Scaffolds
Figure 4.3 Advantages and Disadvantages of Hydrogels
Figure 4.4 Advantages of Microcarriers
Figure 4.5 Techniques Used for Formation of 3D Spheroids
Figure 4.6 Structures of Spinner Flask and Rotating Wall Bioreactors
Figure 6.1 3D Cell Culture System Developers: Distribution by Year of Establishment
Figure 6.2 3D Cell Culture System Developers: Distribution by Company Size
Figure 6.3 3D Cell Culture System Developers: Distribution by Location of Headquarters
Figure 6.4 3D Cell Culture System Developers: Distribution by 3D Cell Culture Format
Figure 6.5 3D Cell Culture System Developers: Distribution by Type of Product
Figure 6.6 3D Cell Culture System Developers: Distribution by Number of 3D Cell Culture Products
Figure 6.7 Heat Map Representation: Distribution by 3D Cell Culture Format and Location of Headquarters
Figure 6.8 Tree Map Representation: Distribution by Company Size and Type of Product
Figure 6.9 World Map Representation: Distribution by Location of Regional Headquarters
Figure 7.1 Scaffold Based Products: Distribution by Status of Development
Figure 7.2 Scaffold Based Products: Distribution by Type of Product
Figure 7.3 Scaffold Based Products: Distribution by Source of 3D Cultured Cells
Figure 7.4 Scaffold Based Products: Distribution by Method Used for Fabrication
Figure 7.5 Scaffold Based Products: Distribution by Material Used for Fabrication
Figure 7.6 Scaffold Based Products: Distribution by Type of Product and Source of 3D Cultured Cells
Figure 7.7 Scaffold Based Products: Distribution by Type of Product and Method Used for Fabrication
Figure 7.8 Scaffold Based Product Developers: Distribution by Year of Establishment
Figure 7.9 Scaffold Based Product Developers: Distribution by Company Size
Figure 7.10 Scaffold Based Product Developers: Distribution by Location of Headquarters
Figure 7.11 Leading Developers: Distribution by Number of Scaffold Based Products
Figure 7.12 Tree Map Representation: Distribution by Type of Product and Company Size
Figure 8.1 Scaffold Free Products: Distribution by Status of Development
Figure 8.2 Scaffold Free Products: Distribution by Type of Product
Figure 8.3 Scaffold Free Products: Distribution by Source of 3D Cultured Cells
Figure 8.4 Scaffold Free Products: Distribution by Method Used for Fabrication
Figure 8.5 Scaffold Free Products: Distribution by Material Used for Fabrication
Figure 8.6 Scaffold Free Products: Distribution by Type of Product and Source of 3D Cultured Cells
Figure 8.7 Scaffold Free Products: Distribution by Type of Product and Method Used for Fabrication
Figure 8.8 Scaffold Free Product Developers: Distribution by Year of Establishment
Figure 8.9 Scaffold Free Product Developers: Distribution by Company Size
Figure 8.10 Scaffold Free Product Developers: Distribution by Location of Headquarters
Figure 8.11 Leading Developers: Distribution by Number of Scaffold Free Products
Figure 8.12 Tree Map Representation: Distribution by Type of Product and Company Size
Figure 9.1 3D Bioreactors: Distribution by Type of 3D Bioreactor
Figure 9.2 3D Bioreactors: Distribution by Working Volume
Figure 9.3 3D Bioreactor Developers: Distribution by Year of Establishment
Figure 9.4 3D Bioreactor Developers: Distribution by Company Size
Figure 9.5 3D Bioreactor Developers: Distribution by Location of Headquarters
Figure 9.6 Leading Developers: Distribution by Number of 3D Bioreactors
Figure 10.1 Key Application Areas of 3D Cell Culture Systems
Figure 10.2 3D Cell Culture Systems in Cancer Research
Figure 10.3 3D Cell Culture Systems in Drug Discovery and Toxicity Screening
Figure 10.4 Methods Used for Embryoid Body Formation
Figure 10.5 Top-Down and Bottom-Up Approaches for Tissue Engineering
Figure 10.6 3D Cell Culture Systems: Distribution by Key Application Areas
Figure 10.7 3D Cell Culture Systems: Distribution by Key Application Areas and 3D Cell Culture Format
Figure 10.8 Scaffold Based 3D Products: Distribution by Key Application Areas
Figure 10.9 Scaffold Free 3D Products: Distribution by Key Application Areas
Figure 10.10 3D Bioreactors: Distribution by Key Application Areas
Figure 13.1 Key Features of 3D Perfusion Bioreactors
Figure 13.2 MagDrive and AirDrive Mechanisms for PBS Bioreactors
Figure 13.3 Advantages of Rotary Cell Culture System (RCCS)
Figure 14.1 Funding and Investments: Distribution of Recipient Companies by Year of Establishment and Type of Funding, 2015-Q3 2020
Figure 14.2 Funding and Investments: Cumulative Number of Funding Instances by Year, 2015 – Q3 2020
Figure 14.3 Funding and Investments: Cumulative Amount Invested, 2015 – Q3 2020 (USD Million)
Figure 14.4 Funding and Investments: Distribution of Instances by Type of Funding, 2015 – Q3 2020
Figure 14.5 Funding and Investments: Year-Wise Distribution of Instances and Type of Funding, 2015 – Q3 2020
Figure 14.6 Funding and Investments: Distribution by Amount Invested and Type of Funding, 2015 – Q3 2020 (USD Million)
Figure 14.7 Funding and Investments: Year-Wise Distribution of Amount Invested and Type of Funding, 2015 – Q3 2020
Figure 14.8 Funding and Investments: Distribution by Number of Instances and Amount Invested by 3D Cell Culture Format, 2015 – Q3 2020
Figure 14.9 Funding and Investments: Distribution by Number of Instances and Amount Invested by Type of Product, 2015 – Q3 2020
Figure 14.10 Funding and Investments: Distribution by Geography
Figure 14.11 Funding and Investments: Regional Distribution by Total Amount Invested, 2015 – Q3 2020
Figure 14.12 Most Active Players: Distribution by Number of Funding Instances, 2015 – Q3 2020
Figure 14.13 Most Active Players: Distribution by Amount Raised, 2015 – Q3 2020 (USD Million)
Figure 14.14 Most Active Investors: Distribution by Number of Funding Instances, 2015–Q3 2020
Figure 14.15 Funding and Investment Summary, 2015 – Q3 2020 (USD Million)
Figure 15.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2015 - Q3 2020
Figure 15.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 15.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Figure 15.4 Partnerships and Collaborations: Distribution by Company Size and Type of Partnership
Figure 15.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 15.6 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 15.7 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 15.8 Partnerships and Collaborations: Distribution by 3D Cell Culture Format
Figure 15.9 Partnerships and Collaborations: Distribution by Year of Partnership and 3D Cell Culture Format
Figure 15.10 Partnerships and Collaborations: Distribution by Type of Partnership and 3D Cell Culture Format
Figure 15.11 Partnerships and Collaborations: Distribution by Type of Product
Figure 15.12 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Product
Figure 15.13 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Figure 15.14 Most Active Players: Distribution by Number of Partnerships
Figure 15.15 Partnerships and Collaborations: Regional Distribution
Figure 15.16 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Figure 16.1 Patent Analysis: Distribution by Type of Patent
Figure 16.2 Patent Analysis: Cumulative Distribution by Publication Year, 2015 - Q3 2020
Figure 16.3 Patent Analysis: Distribution of Granted Patents by Publication Year, 2015 - Q3 2020
Figure 16.4 Patent Analysis: Distribution of Filed Patents Publication Year, 2015 - Q3 2020
Figure 16.5 Patent Analysis: Distribution by Patent Type and Publication Year, 2015 - Q3 2020
Figure 16.6 Patent Analysis: Distribution by Issuing Authority
Figure 16.7 Patent Analysis: Distribution by CPC Symbols
Figure 16.8 Patent Analysis: Distribution by Emerging Focus Area
Figure 16.9 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, 2015 - Q3 2020
Figure 16.10 Leading Patent Assignees (Industry Players): Distribution by Number of Patents
Figure 16.11 Leading Patent Assignees (Non-Industry Players): Distribution by Number of Patents
Figure 16.12 Patent Analysis: Distribution by Patent Age, 2000-2020
Figure 16.13 Patent Analysis: Distribution by Proprietary Scoring Criteria
Figure 16.14 Patent Analysis: Valuation Analysis
Figure 17.1 Global 3D Cell Culture Market, 2020-2030 (USD Million)
Figure 17.2 Global 3D Cell Culture Market: Distribution by Business Segment, 2020 and 2030
Figure 17.3 3D Cell Culture Systems Market, 2020-2030 (USD Million)
Figure 17.4 3D Cell Culture Consumables Market, 2020-2030 (USD Million)
Figure 17.5 3D Cell Culture Services Market, 2020-2030 (USD Million)
Figure 17.6. Global 3D Cell Culture Systems Market: Distribution by 3D Cell Culture Format, 2020-2030
Figure 17.7 3D Cell Culture Systems Market for Scaffold Based Products, 2020-2030 (USD Million)
Figure 17.8 3D Cell Culture Systems Market for Scaffold Free Products, 2020-2030 (USD Million)
Figure 17.9 3D Cell Culture Systems Market for 3D Bioreactors, 2020-2030 (USD Million)
Figure 17.10 Global 3D Cell Culture Systems Market: Distribution by Type of Product, 2020 and 2030
Figure 17.11 3D Cell Culture Systems Market for Attachment Resistant Surfaces, 2020-2030 (USD Million)
Figure 17.12 3D Cell Culture Systems Market for Hydrogels / ECMs, 2020-2030 (USD Million)
Figure 17.13 3D Cell Culture Systems Market for Micropatterned Surface, 2020-2030 (USD Million)
Figure 17.14 3D Cell Culture Systems Market for Microcarriers, 2020-2030 (USD Million)
Figure 17.15 3D Cell Culture Systems Market for Microfluidic Systems, 2020-2030 (USD Million)
Figure 17.16 3D Cell Culture Systems Market for Solid Scaffolds, 2020-2030 (USD Million)
Figure 17.17 3D Cell Culture Systems Market for Suspension Cultures, 2020-2030 (USD Million)
Figure 17.18 Global 3D Cell Culture Systems Market: Distribution by Area of Application, 2020 and 2030
Figure 17.19 3D Cell Culture Systems Market for Cancer Research, 2020-2030 (USD Million)
Figure 17.20 3D Cell Culture Systems Market for Drug Discovery and Toxicity Testing, 2020-2030 (USD Million)
Figure 17.21 3D Cell Culture Systems Market for Stem Cell Research, 2020-2030 (USD Million)
Figure 17.22 3D Cell Culture Systems Market for Regenerative Medicine and Tissue Engineering, 2020-2030 (USD Million)
Figure 17.23 Global 3D Cell Culture Systems Market: Distribution by Purpose, 2020-2030
Figure 17.24 3D Cell Culture Systems Market for Research Use, 2020-2030 (USD Million)
Figure 17.25 3D Cell Culture Systems Market for Therapeutic Use, 2020-2030 (USD Million)
Figure 17.26 Global 3D Cell Culture Systems Market: Distribution by Geography, 2020- 2030
Figure 17.27 3D Cell Culture Systems Market in North America, 2020-2030 (USD Million)
Figure 17.28 3D Cell Culture Systems Market in Europe, 2020-2030 (USD Million)
Figure 17.29 3D Cell Culture Systems Market in Asia-Pacific, 2020-2030 (USD Million)
Figure 17.30 3D Cell Culture Systems Market in Latin America, 2020-2030 (USD Million)
Figure 17.31 3D Cell Culture Systems Market in Middle East and North Africa (MENA), 2020-2030 (USD Million)
Figure 17.32 3D Cell Culture Systems Market in Rest of the World, 2020-2030 (USD Million)
Figure 17.33 Global 3D Cell Culture Systems Market: Distribution by Leading Players, 2020
Figure 17.34 Global 3D Cell Culture Systems Market: Conservative, Base and Optimistic Scenarios, 2020, 2025 and 2030 (USD Million)
Figure 18.1 Survey Insights: Distribution of Respondents by Year of Establishment of the Company
Figure 18.2 Survey Insights: Distribution of Respondents by Company Size
Figure 18.3 Survey Insights: Distribution of Respondents by Location of Company Headquarters (Region-Wise)
Figure 18.4 Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-Wise)
Figure 18.5 Survey Insights: Distribution of Respondents by Designation and Seniority Level
Figure 18.6 Survey Insights: Distribution by Focus Area
Figure 18.7 Survey Insights: Distribution by Type of 3D Cell Culture Products Offered
Figure 18.8 Survey Insights: Distribution by Status of Development of Product(s)
Figure 18.9 Survey Insights: Distribution by Method of Fabrication Used
Figure 18.10 Survey Insights: Distribution by Source of Cultured Cells
Figure 18.11 Survey Insights: Distribution by Key Applications
Figure 18.12 Survey Insights: Distribution by 3D Cell Culture Services Offered
Figure 18.13 Survey Insights: Distribution by Current and Future Market Opportunity, 2020 and 2030
Figure 19.1 3D Cell Culture Systems Market: Concluding Remarks
LIST OF TABLES
Table 3.1 Morphology of Cells in a Culture
Table 3.2 Differences between 2D and 3D Cell Cultures
Table 3.3 Features of 3D Spheroids generated via 3D Cell Culture Systems
Table 4.1 Advantages and Disadvantages of Scaffold Based and Scaffold Free Systems
Table 4.2 Advantages and Disadvantages of Natural and Synthetic Scaffolds
Table 4.3 Advantages and Disadvantages of Natural and Synthetic Hydrogels
Table 4.4 Cell Cultures Used in Magnetic Levitation
Table 4.5 Origin and Culture Techniques Used for Organoids
Table 5.1 Advantages and Disadvantages of Methods Used for Fabrication for Porous Scaffolds
Table 5.2 3D Cell Culture Studies Using Porous Scaffolds
Table 5.3 Methods for Fabrication Used of Fibrous Scaffolds
Table 5.4 Advantages and Disadvantages of Methods Used for Fabrication of Fibrous Scaffolds
Table 5.5 3D Cell Culture Studies Using Fibrous Scaffolds
Table 5.6 Advantages and Disadvantages of Methods Used for Fabrication of Hydrogels
Table 5.7 3D Cell Culture Studies Using Hydrogels
Table 5.8 Advantages and Disadvantages of Methods Used for Fabrication of Custom Scaffolds
Table 5.9 3D Cell Culture Studies Using Custom Scaffolds
Table 5.10 Advantages and Disadvantages of Methods Used for Fabrication of Microspheres
Table 5.11 3D Cell Culture Studies Using Microspheres
Table 5.12 3D Cell Culture Studies Using Native Scaffolds
Table 6.1 3D Cell Culture Systems: List of Developers
Table 6.2 3D Cell Culture Systems: List of Service Providers
Table 6.3 3D Cell Culture Systems: List of Assays, Kits and Reagents
Table 7.1 Scaffold Based Products: List of Products
Table 7.2 Scaffold Based Products: List of Developers
Table 8.1 Scaffold Free Products: List of Products
Table 8.2 Scaffold Free Products: List of Developers
Table 9.1 3D Bioreactors: List of Products
Table 9.2 3D Bioreactors: List of Developers
Table 10.1 Scaffold Based Products: Information on Key Application Areas
Table 10.2 Scaffold Free Products: Information on Key Application Areas
Table 10.3 3D Bioreactors: Information on Key Application Areas
Table 11.1 Scaffold Based Products (Hydrogel / ECM): List of Companies Profiled
Table 11.2 3D Biotek: Company Snapshot
Table 11.3 3D Biotek: Key Characteristics of Hydrogels / ECMs
Table 11.4 Advanced Biomatrix: Company Snapshot
Table 11.5 Advanced Biomatrix: Key Characteristics of Hydrogels / ECMs
Table 11.6 Advanced Biomatrix: Recent Developments and Future Outlook
Table 11.7 Alphabioregen: Company Snapshot
Table 11.8 Alphabioregen: Key Characteristics of Hydrogels / ECMs
Table 11.9 Corning Life Sciences: Company Snapshot
Table 11.10 Corning Life Sciences: Key Characteristics of Hydrogels / ECMs
Table 11.11 Corning Life Sciences: Recent Developments and Future Outlook
Table 11.12 REPROCELL: Company Snapshot
Table 11.13 REPROCELL: Key Characteristics of Hydrogels / ECMs
Table 11.14 REPROCELL: Recent Developments and Future Outlook
Table 12.1 Scaffold Free Products (Organ-on-Chip): List of Companies Profiled
Table 12.2 CN Bio Innovations: Company Snapshot
Table 12.3 CN Bio Innovations: Information on Funding Instances
Table 12.4 CN Bio Innovations: Key Characteristics of Organ-on-Chips Products
Table 12.5 CN Bio Innovations: Recent Developments and Future Outlook
Table 12.6 Emulate: Company Snapshot
Table 12.7 Emulate: Information on Funding Instances
Table 12.8 Emulate: Key Characteristics of Organ-on-Chips Products
Table 12.9 Emulate: Recent Developments and Future Outlook
Table 12.10 InSphero: Company Snapshot
Table 12.11 InSphero: Information on Funding Instances
Table 12.12 InSphero: Key Characteristics of Organ-on-Chips Products
Table 12.13 InSphero: Recent Developments and Future Outlook
Table 12.14 Mimetas: Company Snapshot
Table 12.15 Mimetas: Information on Funding Instances
Table 12.16 Mimetas: Key Characteristics of Organ-on-Chips Products
Table 12.17 Mimetas: Recent Developments and Future Outlook
Table 12.18 Mimetas: Company Snapshot
Table 12.19 Mimetas: Information on Funding Instances
Table 12.20 Mimetas: Key Characteristics of Organ-on-Chips Products
Table 12.21 Mimetas: Recent Developments and Future Outlook
Table 12.22 TissUse: Company Snapshot
Table 12.23 TissUse: Key Characteristics of Organ-on-Chips Products
Table 12.24 TissUse: Recent Developments and Future Outlook
Table 13.1 3D Bioreactors: List of Companies Profiled
Table 13.2 BISS TGT: Company Snapshot
Table 13.3 BISS TGT: Key Characteristics of 3D Bioreactors
Table 13.4 BISS TGT: Recent Developments and Future Outlook
Table 13.5 Celartia: Company Snapshot
Table 13.6 Celartia: Key Characteristics of 3D Bioreactors
Table 13.7 Cell Culture: Company Snapshot
Table 13.8 Cell Culture: Key Characteristics of 3D Bioreactors
Table 13.9 CESCO Bioengineering: Company Snapshot
Table 13.10 CESCO Bioengineering: Key Characteristics of 3D Bioreactors
Table 13.11 EBERS: Company Snapshot
Table 13.12 EBERS: Key Characteristics of 3D Bioreactors
Table 13.13 EBERS: Recent Developments and Future Outlook
Table 13.14 Flexcell International: Company Snapshot
Table 13.15 Flexcell International: Key Characteristics of 3D Bioreactors
Table 13.16 PBS Biotech: Company Snapshot
Table 13.17 PBS Biotech: Key Characteristics of 3D Bioreactors
Table 13.18 Synthecon: Company Snapshot
Table 13.19 Synthecon: Key Characteristics of 3D Bioreactors
Table 14.1 Funding and Investments: Information on Year of Investment, Type of Funding, Amount Raised and Investor, 2015 - Q3 2020
Table 14.2 Funding and Investments: Information on Year of Establishment, Location of Headquarters of Recipients, Focus Area, and Type of Product, 2015 - Q3 2020
Table 15.1 Partnerships and Collaborations: Information on Year of Agreement, Type of Partnership Model, and Partner, 2015 - Q3 2020
Table 15.2 Partnerships and Collaborations: Information on Type of Agreement, Focus Area, and Type of Product, 2015 - Q3 2020
Table 16.1 Patent Analysis: CPC Symbols
Table 16.2 Patent Analysis: Most Popular CPC Symbols
Table 16.3 Patent Analysis: List of Top 10 CPC Symbols
Table 16.4 Patent Analysis: List of Relatively High Value Patents
Table 17.1 Global 3D Cell Culture Systems Market: Key Assumptions Related to Distribution by Type of Products
Table 18.1 Survey Insights: Overview of Respondents
Table 18.2 Survey Insights: Designation and Seniority Level
Table 18.3 Survey Insights: Focus Area of the Company
Table 18.4 Survey Insights: Type of 3D Cell Culture Products Offered
Table 18.5 Survey Insights: Status of Development of Product(s)
Table 18.6 Survey Insights: Method of Fabrication Used
Table 18.7 Survey Insights: Source of 3D Cultured Cells
Table 18.8 Survey Insights: Key Areas of Application
Table 18.9 Survey Insights: 3D Cell Culture Services Offered
Table 18.10 Survey Insights: Current Market Opportunity (2020)
Table 18.11 Survey Insights: Future Market Opportunity (2030)
Table 20.1 Cellendes: Company Snapshot
Table 20.2 Synthecon: Company Snapshot
Table 20.3 BRTI Life Sciences: Company Snapshot
Table 20.4 Kirkstall: Company Snapshot
Table 20.5 QGel: Company Snapshot
Table 20.6 Xylyx Bio: Company Snapshot
Table 20.7 InSphero: Company Snapshot
Table 20.8 GSI: Company Snapshot
Table 20.9 Nanofiber Solutions: Company Snapshot
Table 21.1 3D Cell Culture 7System Developers: Distribution by Year of Establishment
Table 21.2 3D Cell Culture System Developers: Distribution by Company Size
Table 21.3 3D Cell Culture System Developers: Distribution by Location of Headquarters
Table 21.4 3D Cell Culture System Developers: Distribution by 3D Cell Culture Format
Table 21.5 3D Cell Culture System Developers: Distribution by Type of Product
Table 21.6 3D Cell Culture System Developers: Distribution by Number of Products
Table 21.7 Heat Map Representation: Distribution by 3D Cell Culture Format and Location of Headquarters
Table 21.8 Tree Map Representation: Distribution by Company Size and Type of Product
Table 21.9 World Map Representation: Distribution by Location of Regional Headquarters
Table 21.10 Scaffold Based Products: Distribution by Status of Development
Table 21.11 Scaffold Based Products: Distribution by Type of Product
Table 21.12 Scaffold Based Products: Distribution by Source of 3D Cultured Cells
Table 21.13 Scaffold Based Products: Distribution by Method Used for Fabrication
Table 21.14 Scaffold Based Products: Distribution by Material Used for Fabrication
Table 21.15 Scaffold Based Products: Distribution by Type of Product and Source of 3D Cultured Cells
Table 21.16 Scaffold Based Products: Distribution by Type of Product and Method Used for Fabrication
Table 21.17 Scaffold Based Product Developers: Distribution by Year of Establishment
Table 21.18 Scaffold Based Product Developers: Distribution by Company Size
Table 21.19 Scaffold Based Product Developers: Distribution by Location of Headquarters
Table 21.20 Leading Developers: Distribution by Number of Scaffold Based Products
Table 21.21 Tree Map Representation: Distribution by Type of Product and Company Size
Table 21.22 Scaffold Free Products: Distribution by Status of Development
Table 21.23 Scaffold Free Products: Distribution by Type of Product
Table 21.24 Scaffold Free Products: Distribution by Source of 3D Cultured Cells
Table 21.25 Scaffold Free Products: Distribution by Method Used for Fabrication
Table 21.26 Scaffold Free Products: Distribution by Material Used for Fabrication
Table 21.27 Scaffold Free Products: Distribution by Type of Product and Source of 3D Cultured Cells
Table 21.28 Scaffold Free Products: Distribution by Type of Product and Method Used for Fabrication
Table 21.29 Scaffold Free Product Developers: Distribution by Year of Establishment
Table 21.30 Scaffold Free Product Developers: Distribution by Company Size
Table 21.31 Scaffold Free Product Developers: Distribution by Location of Headquarters
Table 21.32 Leading Developers: Distribution by Number of Scaffold Free Products
Table 21.33 Tree Map Representation: Distribution by Type of Product and Company Size
Table 21.34 3D Bioreactors: Distribution by Type of 3D Bioreactor
Table 21.35 3D Bioreactors: Distribution by Working Volume
Table 21.36 3D Bioreactor Developers: Distribution by Year of Establishment
Table 21.37 3D Bioreactor Developers: Distribution by Company Size
Table 21.38 3D Bioreactor Developers: Distribution by Location of Headquarters
Table 21.39 Leading Developers: Distribution by Number of 3D Bioreactors
Table 21.40 3D Cell Culture Systems: Distribution by Key Application Areas
Table 21.41 3D Cell Culture Systems: Distribution by Key Application Areas and 3D Cell Culture Format
Table 21.42 Scaffold Based Products: Distribution by Key Application Areas
Table 21.43 Scaffold Free Products: Distribution by Key Application Areas
Table 21.44 3D Bioreactors: Distribution by Key Application Areas
Table 21.45 Funding and Investments: Distribution of Recipient Companies by Year of Establishment and Type of Funding, 2015-Q3 2020
Table 21.46 Funding and Investments: Cumulative Number of Instances by Year, 2015–Q3 2020
Table 21.47 Funding and Investments: Cumulative Amount Invested, 2015–Q3 2020 (USD Million)
Table 21.48 Funding and Investments: Distribution of Instances by Type of Funding, 2015–Q3 2020
Table 21.49 Funding and Investments: Year-Wise Distribution by Number of Instances and Type of Funding, 2015 – Q3 2020
Table 21.50 Funding and Investments: Distribution of Amount Invested by Type of Funding, 2015 – Q3 2020 (USD Million)
Table 21.51 Funding and Investments: Year-Wise Distribution of Amount Invested and Type of Funding, 2015 – Q3 2020
Table 21.52 Funding and Investments: Distribution of Instances and Amount Invested by 3D Cell Culture Format, 2015–Q3 2020
Table 21.53 Funding and Investments: Distribution of Instances and Amount Invested by Type of Product, 2015–Q3 2020
Table 21.54 Funding and Investments: Distribution by Geography
Table 21.55 Funding and Investments: Regional Distribution by Total Amount Invested, 2015–Q3 2020
Table 21.56 Most Active Players: Distribution by Number of Funding Instances, 2015–Q3 2020
Table 21.57 Most Active Players: Distribution by Amount Raised, 2015–Q3 2020 (USD Million)
Table 21.58 Most Active Investors: Distribution by Funding Instances, 2015–Q3 2020
Table 21.59 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2015-Q3 2020
Table 21.60 Partnerships and Collaborations: Distribution by Type of Partnership
Table 21.61 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Table 21.62 Partnerships and Collaborations: Distribution by Company Size and Type of Partnership
Table 21.63 Partnerships and Collaborations: Distribution by Type of Partner
Table 21.64 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 21.65 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 21.66 Partnerships and Collaborations: Distribution by 3D Cell Culture Format
Table 21.67 Partnerships and Collaborations: Distribution by Year of Partnership and 3D Cell Culture Format
Table 21.68 Partnerships and Collaborations: Distribution by Type of Partnership and 3D Cell Culture Format
Table 21.69 Partnerships and Collaborations: Distribution by Type of Product
Table 21.70 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Product
Table 21.71 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Table 21.72 Most Active Players: Distribution by Number of Partnerships
Table 21.73 Partnerships and Collaborations: Regional Distribution
Table 21.74 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 21.75 Patent Analysis: Distribution by Type of Patent
Table 21.76 Patent Analysis: Cumulative Distribution by Publication Year, 2015-Q3 2020
Table 21.77 Patent Analysis: Distribution of Granted Patents by Publication Year, 2015-Q3 2020
Table 21.78 Patent Analysis: Distribution of Filed Patents Publication Year, 2015-Q3 2020
Table 21.79 Patent Analysis: Distribution by Number of Patent Type and Publication Year, 2015-Q3 2020
Table 21.80 Patent Analysis: Distribution by Issuing Authorities Involved
Table 21.81 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, 2015-Q3 2020
Table 21.82 Leading Patent Assignees (Industry Players): Distribution by Number of Patents
Table 21.83 Leading Patent Assignees (Non-Industry Players): Distribution by Number of Patents
Table 21.84 Patent Analysis: Distribution by Patent Age, 2000-2020
Table 21.85 Patent Analysis: Valuation Analysis
Table 21.86 Global 3D Cell Culture Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.87 Global 3D Cell Culture Market: Distribution by Business Segment, 2020 and 2030
Table 21.88 3D Cell Culture Systems Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.89 3D Cell Culture Consumables Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.90 3D Cell Culture Services Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.91 Global 3D Cell Culture Systems Market: Distribution by 3D Cell Culture Format, 2020 and 2030
Table 21.92 3D Cell Culture Systems Market for Scaffold based Products, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.93 3D Cell Culture Systems Market for Scaffold Free Products, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.94 3D Cell Culture Systems Market for Market 3D Bioreactors, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.95 Global 3D Cell Culture Systems Market: Distribution by Type of Product, 2020 and 2030
Table 21.96 3D Cell Culture Systems Market for Attachment Resistant Surfaces, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.97 3D Cell Culture Systems Market for Hydrogels / ECMs, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.98 3D Cell Culture Systems Market for Micropatterned Surface, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.99 3D Cell Culture Systems Market for Microcarriers, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.100 3D Cell Culture Systems Market for Microfluidic Systems, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.101 3D Cell Culture Systems Market for Solid Scaffolds, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.102 3D Cell Culture Systems Market for Suspension Culture Systems, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.103 Global 3D Cell Culture Systems Market: Distribution by Area of Application, 2020 and 2030
Table 21.104 3D Cell Culture Systems Market for Cancer Research, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.105 3D Cell Culture Systems Market for Drug Discovery and Toxicity Testing, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.106 3D Cell Culture Systems Market for Stem Cell Research, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.107 3D Cell Culture Systems Market for Regenerative Medicine and Tissue Engineering, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.108 Global 3D Cell Culture Systems Market: Distribution by Purpose, 2020 and 2030
Table 21.109 3D Cell Culture Systems Market for Research Use, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.110 3D Cell Culture Systems Market for Therapeutic Use, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.111 Global 3D Cell Culture Systems Market: Distribution by Geography, 2020 and 2030
Table 21.112 3D Cell Culture Systems Market in North America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.113 3D Cell Culture Systems Market in Europe, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.114 3D Cell Culture Systems Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.115 3D Cell Culture Systems Market in Latin America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.116 3D Cell Culture Systems Market in Middle East and North Africa (MENA), Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.117 3D Cell Culture Systems Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 21.118 Global 3D Cell Culture Systems Market: Distribution by Leading Players, 2020
Table 21.119 Global 3D Cell Culture Systems Market: Conservative, Base and Optimistic Scenarios, 2020, 2025 and 2030 (USD Million)
Table 21.120 Survey Insights: Distribution of Respondents by Year of Establishment of Company
Table 21.121 Survey Insights: Distribution of Respondents by Company Size
Table 21.122 Survey Insights: Distribution of Respondents by Location of Company Headquarters (Region-Wise)
Table 21.123 Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-Wise)
Table 21.124 Survey Insights: Distribution of Respondents by Designation and Seniority Level
Table 21.125 Survey Insights: Distribution by Focus Area
Table 21.126 Survey Insights: Distribution by Type of 3D Cell Culture Products Offered
Table 21.127 Survey Insights: Distribution by Development Status of Product(s)
Table 21.128 Survey Insights: Distribution by Method of Fabrication Used
Table 21.129 Survey Insights: Distribution by Source of Cultured Cells
Table 21.130 Survey Insights: Distribution by Key Application Areas
Table 21.131 Survey Insights: Distribution by 3D Cell Culture Services Offered
Table 21.132 Survey Insights: Distribution by Current and Future Market Opportunity, 2020 and 2030

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook